DNA methylation is the most fully characterized epigenetic mechanism, playing a key role in regulating global and specific gene expression profiles and promoting important cellular processes. Aberrant DNA methylation is associated with a variety of human diseases, such as ischemic stroke. The role of DNA methylation in cerebral ischemia is multifaceted, with genome-wide and gene-specific effects that influence vulnerability to CNS injury. Molecular studies using animal models of stroke have shown that increased levels of DNA methylation in ischemic brain tissue lead to increased brain damage. Investigating the role of DNA methylation in neuroprotection and functional recovery after stroke could contribute to the development and application of novel therapeutic strategies for stroke.
Fig. 1. Analysis of DNA methylome in post-TE stroke BBB recovery. (Phillips et al., 2023)
Ace Therapeutics' multidisciplinary team employs advanced technologies to help clients analyze the mechanisms of neuronal death and neural repair through DNA methylation regulation after stroke.
We provide RNA sequencing and simplified representative bisulfite sequencing (RRBS) for the discovery of DNA methylation-related targets in stroke. DNA methylation-related targets that have been identified include:
DNMT | MTHFR | NKCC1 | THBS1 |
ApoE | CDKN2B | TRAF3 | PPM1A |
EAAT2 | TIMP-2 | MMP-9 | PPM1A |
MTHFR | LEF1 | SPRR1 | RAG |
BDNF | ND2, ND3, ND4L, ND5, ND6, and COX3 | Timp-2 | Arid5a, Nptx2, Stc2 |
We help clients analyze the role of specific gene regulation mediated by DNA methylation in the pathophysiology of stroke in animal models of stroke and in vitro experiments.
Ace Therapeutics is committed to providing experimental data on the regulation of DNA methylation in post-stroke neuroprotection and neuronal repair mechanisms. Through advanced methodologies and partnerships, we aim to accelerate the R&D process for our clients to develop new therapeutic strategies for stroke. If you are interested in our services, please do not hesitate to contact us!
We are committed to accelerating progress in stroke research and drug development.